MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, MRSN made $11,009K in revenue. -$7,545K in net income. Net profit margin of -68.53%.

Income Overview

Revenue
$11,009K
Net Income
-$7,545K
Net Profit Margin
-68.53%
EPS
-$1.51
Unit: Thousand (K) dollars

Income Statement
2025-09-30
2025-06-30
2025-03-31
2024-12-31
Collaboration revenue
11,009 3,056 2,754 18,161*
Research and development
12,182 16,218 18,341 25,575*
General and administrative
6,303 7,415 8,925 10,263*
Restructuring expenses
191 3,940 --
Total operating expenses
18,676 27,573 27,266 35,837*
Interest income
516 895 1,164 2,224*
Interest expense
394 674 775 921*
Total other income, net
122 221 389 1,303*
Loss before income taxes
-7,545 ---
Income tax expense
0 ---836*
Net loss
-7,545 -24,296 -24,123 -15,538*
Unrealized gain (loss) on marketable securities, net of tax
0 0 -10 -173*
Comprehensive loss
-7,545 -24,296 -24,133 -15,712
Basic EPS
-1.51 -4.87 -0.19 -0.128
Diluted EPS
-1.51 -4.87 -0.19 -0.128
Basic Average Shares
4,992,639 4,986,784 124,466,113 122,456,752
Diluted Average Shares
4,992,639 4,986,784 124,466,113 122,456,752
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Comprehensive loss-$7,545K (33.84%↑ Y/Y)Net loss-$7,545K (34.40%↑ Y/Y)Interest income$516K (-73.83%↓ Y/Y)Loss before incometaxes-$7,545K (31.92%↑ Y/Y)Collaboration revenue$11,009K (-12.61%↓ Y/Y)Total other income,net$122K (-87.63%↓ Y/Y)Interest expense$394K (-60.04%↓ Y/Y)Total operatingexpenses$18,676K (-24.29%↓ Y/Y)Research and development$12,182K (-17.71%↓ Y/Y)General andadministrative$6,303K (-36.10%↓ Y/Y)Restructuring expenses$191K

Mersana Therapeutics, Inc. (MRSN)

Mersana Therapeutics, Inc. (MRSN)